Popular
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CEChairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
CME/CEProgress in Breast Cancer Care: Translating SABCS Data Into Practice
Double-Class Refractory CLL in Community Practice: Current and Future Management
CME/CEDouble-Class Refractory CLL in Community Practice: Current and Future Management
Understanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
AudioAbstractsUnderstanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
Breaking Ground: 2025 Milestones in Cushing Syndrome and Looking Forward to 2026
CME/CEBreaking Ground: 2025 Milestones in Cushing Syndrome and Looking Forward to 2026
Programs
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
CME/CEFrontline Insights: Emerging Therapeutic Strategies in HNSCC
Understanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
AudioAbstractsUnderstanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
From Pixels to Practice: Advancing HCM Care With Multimodality Imaging
CME/CEFrom Pixels to Practice: Advancing HCM Care With Multimodality Imaging
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CEFrom Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CENavigating Treatment Sequencing After Frontline Treatment Failure in CLL
Clinical Practice
Treating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA
Medical Industry FeatureTreating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA
Breaking Ground: 2025 Milestones in Cushing Syndrome and Looking Forward to 2026
CME/CEBreaking Ground: 2025 Milestones in Cushing Syndrome and Looking Forward to 2026
Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event
MinuteCE®Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event
The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiersThe Burden of Cognitive Dysfunction in Multiple Sclerosis
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CEAdvancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Doctors Lounge
“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
The Convergence“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
The Convergence"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
Next-Gen Clinical Monitoring: Predicting Inpatient Decline with AI-Driven Alerts
The ConvergenceNext-Gen Clinical Monitoring: Predicting Inpatient Decline with AI-Driven Alerts
"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
The Convergence"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
Disparities in Acne Prescribing Patterns Highlight Structural and Racial Gaps
Clinician's RoundtableDisparities in Acne Prescribing Patterns Highlight Structural and Racial Gaps
Disparities in Osteoporosis Care: Addressing Screening and Treatment Barriers
On the Frontlines of OsteoporosisDisparities in Osteoporosis Care: Addressing Screening and Treatment Barriers
CME
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CEChairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
CME/CEGDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF
MinuteCE®When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CEPatient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
Industry Feature
Anti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation
Medical Industry FeatureAnti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation
Research Uncovers a Potential Biomarker for Postpartum Depression Risk
Medical Industry FeatureResearch Uncovers a Potential Biomarker for Postpartum Depression Risk
Improving Outcomes and Reducing Delays in Orthopedic Surgery
Medical Industry FeatureImproving Outcomes and Reducing Delays in Orthopedic Surgery
Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Medical Industry FeatureAgitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Targeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Medical Industry FeatureTargeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Amyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression
Medical Industry FeatureAmyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression